Search

Sustainability

Actions we're taking to reduce the environmental impact of our flagship event: the EHA Congress.

Read more

Mesenchymal Stromal Cells (MSC)

The focus of the current MSC Specialized Working Group is to better understand mechanisms through which MSCs could modulate immune responses, identify individual cells belonging to the innate and adaptive immune responses that interact with MSCs and define the molecular…

Read more

Genetic Predisposition to Blood Cancer (Rare diseases)

The objectives of the group are:

Share and extend clinical knowledge on the diagnosis and treatment of hematologic malignancies with germline predisposition.

Read more

Does the patient with myelofibrosis feel better through Pacritinib?

Pacritinib is an oral next-generation multikinase inhibitor with specificity for JAK2 and FLT3 being evaluated to treat myelofibrosis in two Phase 3 trials.

Read more

Treatment, medicine and hematology research: What patients want and doctors need (to know)

Jan Geissler, a Patient Advocate remarked about the Congress: “Over and above scientific updates, much can be achieved in partnership between hematologists and patients.

Read more

Regulatory affairs & scientific relations

EHA’s regulatory work: European Medicines AgencyMost of EHA’s regulatory work entails collaboration with the European Medicines Agency (EMA).

Read more